Aurobindo breaks ground on New Jersey facility

pills

Aurobindo is starting to build on its pledge to expand operations in New Jersey, literally.  

The Indian drugmaker this week broke ground on the 567,000-square-foot facility that is slated to include a manufacturing and distribution center and warehouse, according to NJ.com. The company has said it expects to eventually have 400 to 500 jobs there.

The expansions come as Aurobindo is building its business in the U.S. It has said that it has about 45 generic drug applications pending before the FDA.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

In addition to the New Jersey project, the drugmaker announced plans in April to spend $31.7 million to turn a former medical facility in Durham, NC, into a manufacturing site. When complete, that project is slated to have 275 workers.

The drugmaker said it decided it would be able to get expanded U.S. production faster by retrofitting a former Teleflex Medical facility near Research Triangle Park, than to build a new manufacturing facility at its New Jersey campus. Aurobindo has been approved for more than $4.6 million in state and local incentives for the North Carolina project.

- read the NJ.com story

Related Articles: 
Aurobindo moves forward with plans for new U.S. plant 
Aurobindo to move U.S. HQ, manufacturing to North Carolina 
FDA finds faults with one of two Aurobindo plants it inspects

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.